Company profile page - 4SC feature image - 28062019 - JPG

Laboratorios Farmacéuticos ROVI

SP: ROVI

€1138.2m market cap

€20.6 last close

Laboratorios Farmacéuticos ROVI is a fully integrated Spanish speciality pharmaceutical company involved in the development, in-licensing, manufacture and marketing of small molecule and speciality biologic drugs with a particular expertise in low molecular weight heparin (LMWH).

Investment summary

ROVI is a profitable speciality healthcare company that markets ~40 proprietary and in-licensed products across nine core franchises, mainly in its domestic Spanish market. Since obtaining market authorisation for its internally developed enoxaparin biosimilar (Becat) in multiple countries, ROVI has commenced marketing in several European countries and has signed out-licensing agreements that cover 91 countries globally – key drivers for sales and operating growth in the medium term. In September, ROVI announced it plans to build a new LMWH manufacturing facility over the next three years, doubling its current capacity. R&D progress continues with its proprietary ISM technology. Notably, its risperidone ISM (DORIA), a long-acting injectable for schizophrenia, has recently completed a Phase III study, meeting its pre-specified primary endpoint; regulatory fillings can be expected by 2019/2020.

Y/E Dec
Revenue (€m)
EBITDA (€m)
PBT (€m)
EPS (c)
P/E (x)
P/CF (x)
2017A 277.4 29.9 20.3 39.99 50.8 56.4
2018A 304.8 29.5 19.3 38.76 52.4 119.5
2019E 364.6 45.0 31.6 53.95 37.6 59.9
2020E 391.0 54.2 36.6 62.17 32.7 67.0
Last updated on 18/09/2019
Industry outlook

ROVI has a strong presence in the Spanish heparin market (and select international markets through partners), where it has been manufacturing and marketing its flagship product, Hibor (second-generation LMWH), since 1998.

Last updated on 18/09/2019
Sector
Healthcare
Share price graph
Balance sheet
Forecast net cash (€m) 22
Forecast gearing ratio (%) N/A
Price performance
%
1m
3m
12m
Actual (9.0) 1.0 24.2
Relative* (13.0) 2.0 28.9
52-week high/low €23.2/€14.8
*% relative to local index
Key management
Javier Lopez-Belmonte Encina CFO
Marta Campos Martinez Investor Relations

Content on Laboratorios Farmacéuticos ROVI